Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:26:52.577Z.
Calculation as of: 2026-10-06T14:26:52.577Z.
Quote observation: 2026-10-06T14:24:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 443dbef5a4958c6c8665db428659f78ed614b233762584452a295f0fd6fa7086
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$282.98M
PS Ratio
11.09
TTM Avg
341.11
3Y Avg
260.22
5Y Avg
137.39
Market Cap
$284.38M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
PS Ratio
N/A
TTM Avg
8336935.98
3Y Avg
3234328.97
5Y Avg
2173022.38
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $274.61M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $276.57M | 1.33 | 0.91 | 1.11 | 1.80 |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | 41.93 | 30.89 | 23.00 | 28.64 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A | 6.36 | 62.99 | 58.72 |
| Abeona Therapeutics Inc. (ABEO)vs › | $282.98M | 11.09 | 341.11 | 260.22 | 137.39 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $284.38M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $286.20M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | 8336935.98 | 3234328.97 | 2173022.38 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $259.91M | 93.19 | 82.20 | 35.74 | 24.54 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-17 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
